PT - JOURNAL ARTICLE AU - Thomas W. McDade AU - Elizabeth M. McNally AU - Aaron S. Zelikovich AU - Richard D’Aquila AU - Brian Mustanski AU - Aaron Miller AU - Lauren A. Vaught AU - Nina L. Reiser AU - Elena Bogdanovic AU - Katherine S. Fallon AU - Alexis R. Demonbreun TI - High seroprevalence for SARS-CoV-2 among household members of essential workers detected using a dried blood spot assay AID - 10.1101/2020.06.01.20119602 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.01.20119602 4099 - http://medrxiv.org/content/early/2020/06/02/2020.06.01.20119602.short 4100 - http://medrxiv.org/content/early/2020/06/02/2020.06.01.20119602.full AB - Objective Serological testing is needed to investigate the extent of transmission of SARS-CoV-2 from front-line essential workers to their household members. However, the requirement for serum/plasma limits serological testing to clinical settings where it is feasible to collect and process venous blood. To address this problem we developed a serological test for SARS-CoV-2 IgG antibodies that requires only a single drop of finger stick capillary whole blood, collected in the home and dried on filter paper (dried blood spot, DBS).Methods An ELISA to the receptor binding domain of the SARS-CoV-2 spike protein was optimized to quantify IgG antibodies in DBS. Samples were self-collected from a community sample of 232 participants enriched with health care workers, including 30 known COVID-19 cases and their household members.Results Among 30 individuals sharing a household with a virus-confirmed case of COVID-19, 80% were seropositive. Of 202 community individuals without prior confirmed acute COVID-19 diagnoses, 36% were seropositive. Of documented convalescent COVID-19 cases from the community, 29 of 30 (97%) were seropositive for IgG antibodies to the receptor binding domain.Conclusion DBS ELISA provides a minimally-invasive alternative to venous blood collection. Early analysis suggests a high rate of transmission among household members. High rates of seroconversion were also noted following recovery from infection. Serological testing for SARSCoV-2 IgG antibodies in DBS samples can facilitate seroprevalence assessment in community settings to address epidemiological questions, monitor duration of antibody responses, and assess if antibodies against the spike protein correlate with protection from reinfection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported with funding from the Canadian Institute for Advanced Research and Center for Genetic Medicine, Northwestern University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Northwestern University Institutional Review Board approved protocols #STU00212457 and #STU00212472.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon written request to the corresponding author.